Core Viewpoint - The company plans to utilize idle funds for entrusted wealth management and securities investment, with a total amount not exceeding RMB 2.9 billion, to enhance the efficiency of fund usage and generate returns for shareholders [2][3][14]. Investment Overview - Investment Purpose: The company aims to improve the efficiency of idle funds while ensuring normal business operations and daily capital needs [3]. - Total Investment Amount: The total investment amount will not exceed RMB 2.9 billion, with RMB 2.3 billion allocated for entrusted wealth management and RMB 600 million for securities investment [2][3][14]. - Investment Duration: The investment period is set for 12 months from the approval date of the board meeting [4][14]. Investment Details - Source of Funds: The funds will come from the company's idle self-owned capital [4]. - Investment Methods: Entrusted wealth management will focus on bank wealth management products, income certificates, and funds, while securities investment will include government bonds, bond repurchase agreements, ETFs, and stocks [4][3]. - Approval Process: The investment plan has been approved by the company's board of directors and does not require shareholder meeting approval [6][14]. Impact on the Company - The use of idle funds for wealth management and securities investment will not affect the company's normal cash flow or operations, and it aims to enhance fund returns and protect shareholder interests [8][14]. - Accounting Treatment: The company will account for the entrusted wealth management and securities investment in accordance with relevant accounting standards, reflecting them in the balance sheet and income statement [8].

Focus 1: Yingfang Micro - The company is planning a major asset restructuring by acquiring controlling stakes in Shanghai Xiaokeli Information Technology Co., Ltd., FIRST TECHNOLOGY CHINA LIMITED, and Shiqing Intelligent Technology (Shanghai) Co., Ltd. through a combination of share issuance and cash payment [1] - The transaction is expected to constitute a significant asset restructuring but will not involve related transactions or restructuring listings. The company's stock will be suspended from trading starting January 6, 2026 [1] Focus 2: Nanxing Co. and Yinglian Co. - Nanxing Co. expects to achieve a net profit of 90 million to 120 million yuan for 2025, recovering from a loss of 175 million yuan in the previous year. The significant profit increase is attributed to reduced goodwill impairment in 2024 [2] - Yinglian Co. anticipates a net profit of 32 million to 42 million yuan for 2025, compared to a loss of approximately 39.67 million yuan in the previous year, driven by growth in the fast-moving consumer goods metal packaging sector [2] Focus 3: Victory Energy - The company has completed its stock trading suspension review and will resume trading on January 6, 2026. No undisclosed significant information affecting stock prices was found during the review [3] Performance Highlights - Whirlpool expects a net profit of approximately 505 million yuan for 2025, a 150% increase from the previous year, due to ongoing transformation and efficiency improvements [4] - Taotao Automotive forecasts a net profit of 800 million to 850 million yuan for 2025, representing an 85.5% to 97.1% increase year-on-year, driven by enhanced operational efficiency and market demand [4] - China National Materials Technology anticipates a net profit of 1.55 billion to 1.95 billion yuan for 2025, a growth of 73.79% to 118.64% compared to the previous year, supported by improved product pricing and sales [4] Investment and Restructuring - Weigao Blood Products plans to issue shares to acquire 100% of Weigao Group Medical Polymer Co., Ltd. for 8.511 billion yuan, significantly enhancing the company's asset scale and profitability [6] - Haopeng Technology is set to raise up to 800 million yuan through a private placement to fund energy storage battery projects [6] Control Changes - Hengshi Technology's control has changed following agreements with New Base Information Technology Group, with the new controlling entity holding 9.55% of the total shares [7] Major Projects - Fulian Precision plans to invest 6 billion yuan in a project to produce 500,000 tons of high-end lithium iron phosphate for energy storage [10] - Penghui Energy's board approved plans to issue H-shares and list on the Hong Kong Stock Exchange [11] Other Announcements - The company intends to repurchase A-shares for employee stock ownership plans, with a total budget of 50 million to 100 million yuan [12] - The company reported a 14.75% year-on-year decline in pig sales, with a revenue drop of 36.06% due to market fluctuations [12]

最新公告列表 近日，辰欣药业发布公告称，公司及控股子公司拟使用不超过29亿元的闲置自有资金进行委托理财及证 券投资，其中委托理财额度不超过23亿元，证券投资额度不超过6亿元，使用期限为董事会审议通过之 日起12个月，资金可滚动使用。投资范围包括银行理财产品、收益凭证、基金、国债、债券、ETF、股 票等。该事项已由公司第五届董事会第十一次会议审议通过，无需提交股东会审议。公司表示将加强风 险控制，防范市场、流动性等风险，并按规定披露相关进展。 截至2026年1月5日收盘，辰欣药业（603367）报收于18.21元，较前一交易日上涨5.14%，最新总市值为 82.45亿元。该股当日开盘17.42元，最高18.25元，最低17.42元，成交额达3.67亿元，换手率为4.52%。 《第五届董事会第十一次会议决议【签字盖章】》 《辰欣药业股份有限公司第五届董事会第十一次会议决议公告》 《辰欣药业股份有限公司关于公司及控股子公司使用闲置自有资金进行委托理财及证券投资的公 告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Chenxin Pharmaceutical (603367) announced plans to utilize idle funds for entrusted wealth management and securities investment, with a total amount not exceeding 2.9 billion yuan, aiming to enhance the efficiency of fund usage and generate higher returns for shareholders [1] Group 1: Investment Plans - The company and its subsidiaries plan to use idle self-owned funds for entrusted wealth management and securities investment, with a total limit of 2.9 billion yuan, including up to 2.3 billion yuan for entrusted wealth management and up to 600 million yuan for securities investment [1] - The investment aims to improve the efficiency of idle funds while ensuring that the company's main business operations and daily capital needs are not affected [1] Group 2: Investment Types - Entrusted wealth management will primarily involve bank wealth management products, income certificates, and funds from financial institutions [1] - Securities investment will focus on government bonds or reverse repos, bonds, ETFs, stocks, and other investments permitted by laws and regulations [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：委托理财的额度用于银行理财产品、收益凭证、基金等 金融机构理财产品；证券投资的额度主要用于国债或国债逆回购、债券、 ETF、股票投资以及法律法规和上海证券交易所规则允许的其他投资行 为。 投资金额：公司及控股子公司拟使用闲置自有资金进行委托理财及 证券投资，合计额度不超过人民币 29 亿元（含），其中委托理财的额度 不超过人民币 23 亿元（含），证券投资的额度不超过人民币 6 亿元（含）。 资金额度使用期限为自本次董事会审议通过本议案之日起 12 个月。 已履行的审议程序：经公司第五届董事会第十一次会议审议通过《关 于公司及控股子公司使用闲置自有资金进行委托理财及证券投资的议 案》，同意公司使用闲置的自有资金进行委托理财和证券投资，本议案 无需提交股东会审议。 特别风险提示：本次委托理财及证券投资过程中面临市场风险、收 益不确定性风险、资金流动性风险、操作风险等。敬请广大投资者注意 投资风险。 证券代码：603367 证券简称：辰欣药业 公告编号：20 ...

辰欣药业股份有限公司 第五届董事会第十一次会议决议 一、董事会会议召开情况 辰欣药业股份有限公司(以下简称 "公司"或"辰欣药业"),第五届董事会第十 一次会议于 2026年1月5日在公司办公楼六楼会议室以现场结合通讯方式召开。本次 董事会会议通知于 2025年 12月 30日以电子邮件、EM 系统 微信、电话等通讯方式 发出。会议应出席董事9名,实际出席会议董事9名。会议由董事长杜振新先生主持, 公司其他高级管理人员列席会议。本次会议的召集和召开程序符合《公司法》等相关 法律法规及《公司章程》的有关规定,会议决议合法、有效。 二、董事会会议审议情况 经与会董事逐项审议,会议通过了如下议案: 1、审议通过《关于公司及控股子公司向银行申请综合授信额度的议案》 基于公司正常生产经营及对外投资业务发展的需要,公司需不时向银行申请贷款 以补充流动资金。结合公司 2025年度实际融资情况及 2026年度经营计划,公司及控 股子公司拟向银行申请不超过人民币 15 亿元的综合授信额度,授信品种包括但不限于 流动资金贷款、长期借款、银行承兑汇票、保函、国内外信用证、贴现、供应链金融 等。提请董事会授权公司管理层根据实际经营情 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2026-001 辰欣药业股份有限公司 第五届董事会第十一次会议决议公告 1、审议通过《关于公司及控股子公司向银行申请综合授信额度的议案》 基于公司正常生产经营及对外投资业务发展的需要，公司需不时向银行申请贷 款以补充流动资金。结合公司 2025 年度实际融资情况及 2026 年度经营计划，公司 及控股子公司拟向银行申请不超过人民币 15 亿元的综合授信额度,授信品种包括但 不限于流动资金贷款、长期借款、银行承兑汇票、保函、国内外信用证、贴现、供 应链金融等。提请董事会授权公司管理层根据实际经营情况的需要，在不超过人民 币 15 亿元的综合授信额度内办理银行融资具体事宜，并授权公司法定代表人及控 股子公司法定代表人签署相关协议和文件。上述授信额度及授权的期限为自本次董 事会批准之日起一年。上述授信额度不等于公司的实际融资金额，实际融资金额应 在授信额度内，并以银行与公司实际发生的融资金额为准，具体融资金额将视公司 运营资金的实际需求来合理确定。 本议案自董事会审议通过之日起生效，公司此前于 2025 年 4 月 1 日审议通过 的《关于公司及控股子公司向银 ...

Core Viewpoint - The company announced plans to utilize idle self-owned funds for entrusted wealth management and securities investment, with a total amount not exceeding 2.9 billion yuan [1] Group 1: Financial Allocation - The total amount for entrusted wealth management is capped at 2.3 billion yuan [1] - The total amount for securities investment is capped at 600 million yuan [1] - The duration for utilizing these funds is set for 12 months from the date of board approval [1]

格隆汇1月5日丨辰欣药业(603367.SH)公布，公司及控股子公司拟使用闲置自有资金进行委托理财及证 券投资，合计额度不超过人民币29亿元（含），其中委托理财的额度不超过人民币23亿元（含），证券 投资的额度不超过人民币6亿元（含）。资金额度使用期限为自本次董事会审议通过本议案之日起12个 月。 ...

格隆汇1月5日丨辰欣药业(603367.SH)公布，公司及控股子公司拟使用闲置自有资金进行委托理财及证 券投资，合计额度不超过人民币29亿元（含），其中委托理财的额度不超过人民币23亿元（含），证券 投资的额度不超过人民币6亿元（含）。资金额度使用期限为自本次董事会审议通过本议案之日起12个 月。 ...